title: The influence of angiotensin-converting enzyme gene of donor and recipient on the function of transplanted kidney.
abstract: One of the genes that is supposed to influence renal graft function is the one encoding angiotensin I-converting enzyme (ACE). It shows polymorphism in the presence (I allele) or absence (D allele) of a 287-base pair fragment. The question arises whether ACE gene polymorphism of the recipient and donor influences renal graft survival. This prospective study included 94 recipients who underwent ACE genotyping (DD, DI, II) and measured their creatinine clearance after cimetidine administration. These factors were correlated with the occurrence of acute or chronic rejection and of pharmacologic treatment of hypertension. In 27 recipients it was possible to obtain the ACE genotype of the donor. Among the recipients, 36 proved to be DD genotype, 38 ID, and 20 II. Among the donors, 10 proved to be DD genotype, 10 ID, and 7 II. The changes in creatinine clearance after cimetidine administration were not significantly different among any of the genotype subgroups. Significantly higher creatinine concentrations were found among recipients with II genotype compared to the combined group of ID and DD among patients not treated with ACE inhibitors, but not among those receiving ACE I after kidney transplantation. No differences were found in the frequency of rejection episodes among the subgroups with different ACE genotypes. No significant influence of donor ACE genotype on renal graft function was observed. In summary, the I/D genotype was not an independent prognostic factor for renal graft survival in the first 4 years after transplantation. Possibly the use of ACE I alters the influence of genotype on some parameters.
authors.affiliation: Department of Nephrology, Pomeranian Academy of Medicine, Western Pomerania, Poland.
authors.forename: J
authors.initials: J
authors.lastname: Kabat-Koperska
authors.forename: M
authors.initials: M
authors.lastname: Baśkiewicz-Masiuk
authors.forename: K
authors.initials: K
authors.lastname: Safranow
authors.forename: E
authors.initials: E
authors.lastname: Gołembiewska
authors.forename: E
authors.initials: E
authors.lastname: Paczkowska
authors.forename: A
authors.initials: A
authors.lastname: Mikłaszewicz
authors.forename: K
authors.initials: K
authors.lastname: Kedzierska
authors.forename: S
authors.initials: S
authors.lastname: Giedrys-Kalemba
authors.forename: B
authors.initials: B
authors.lastname: Machaliński
authors.forename: K
authors.initials: K
authors.lastname: Ciechanowski
mesh_terms: D000328:Adult; D002927:Cimetidine / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D005260:Female; D005838:Genotype; D006801:Humans; D016030:Kidney Transplantation / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D007703:Peptidyl-Dipeptidase A / Q000235:genetics* / Q000627:therapeutic use; D011110:Polymorphism, Genetic; D011446:Prospective Studies; D014019:Tissue Donors
chemical_list: D002927:Cimetidine; D003404:Creatinine; D007703:Peptidyl-Dipeptidase A